Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exendin-4 for Parkinson's disease.

Literature DB >> 34084977

Exendin-4 for Parkinson's disease.

Felipe de Jesús Esparza-Salazar¹, Alma Rosa Lezama-Toledo¹, Germán Rivera-Monroy¹, Cesario V Borlongan¹.

Abstract

This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD. Copyright:

Entities: Chemical Disease Gene Species

Keywords: Exenatide; Parkinson's disease; exendin-4; glucagon-like peptide-1

Year: 2021 PMID： 34084977 PMCID： PMC8057099 DOI： 10.4103/bc.bc_21_21

Source DB: PubMed Journal: Brain Circ ISSN： 2394-8108

20 in total

1. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.

Authors: S M Papa; R Desimone; M Fiorani; E H Oldfield
Journal: Ann Neurol Date: 1999-11 Impact factor: 10.422

Review 2. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.

Authors: Dilan Athauda; Thomas Foltynie
Journal: Neuropharmacology Date: 2017-09-18 Impact factor: 5.250

Review 3. Modulation of striatal projection systems by dopamine.

Authors: Charles R Gerfen; D James Surmeier
Journal: Annu Rev Neurosci Date: 2011 Impact factor: 12.449

Review 4. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.

Authors: Daniel J Drucker
Journal: Cell Metab Date: 2018-04-03 Impact factor: 27.287

5. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.

Authors: David Petri; Martin Pum; Jan Vesper; Joseph P Huston; Alfons Schnitzler
Journal: Behav Brain Res Date: 2013-05-30 Impact factor: 3.332

6. Exenatide and the treatment of patients with Parkinson's disease.

Authors: Iciar Aviles-Olmos; John Dickson; Zinovia Kefalopoulou; Atbin Djamshidian; Peter Ell; Therese Soderlund; Peter Whitton; Richard Wyse; Tom Isaacs; Andrew Lees; Patricia Limousin; Thomas Foltynie
Journal: J Clin Invest Date: 2013-06 Impact factor: 14.808

7. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.

Authors: Justin C Touchon; Cynthia Moore; Julie Frederickson; Charles K Meshul
Journal: Synapse Date: 2004-03-15 Impact factor: 2.562

8. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease.

Authors: M Merello; J Balej; M Delfino; A Cammarota; O Betti; R Leiguarda
Journal: Mov Disord Date: 1999-01 Impact factor: 10.338

9. Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.

Authors: Yazhou Li; Kelli L Vaughan; David Tweedie; Jin Jung; Hee Kyung Kim; Ho-Il Choi; Dong Seok Kim; Julie A Mattison; Nigel H Greig
Journal: Sci Rep Date: 2019-11-20 Impact factor: 4.379